2,2200
08-января-25 15:45:00
15 мин. задержка
Акции
-0,0400
-1,77%
Сегодняшний диапазон
2,1600 - 2,3392
ISIN
N/A
Источник
NASDAQ
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 мар 2024 06:06:46 Источник Nasdaq GlobeNewswire